Integra LifeSciences to Present at Healthcare Conferences in September 2017
PLAINSBORO, N.J., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will present at the Wells Fargo Healthcare Conference and the Morgan Stanley Healthcare Conference in September.
- On Thursday, September 7, 2017 at 10:00 a.m. ET, Glenn Coleman, chief financial officer and corporate vice president of International, will present at the Wells Fargo Healthcare Conference in Boston, MA. A live audio webcast of the presentation can be accessed at Integra's Investor Relations website at http://investor.integralife.com/.
- On Tuesday, September 12, 2017 at 2:05 p.m. ET, Peter Arduini, president and chief executive officer, will present at the Morgan Stanley Healthcare Conference in New York City. A live audio webcast of the presentation can be accessed at Integra's Investor Relations website at http://investor.integralife.com/.
Integra LifeSciences (NASDAQ:IART) is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Michael Beaulieu Director, Investor Relations (609) 750-2827 firstname.lastname@example.org